A perspective on dietary -arginine supplementation in human renal disease 1641 through this pathway [30, 31] . The reaction is catalysed time is achieved by binding to specific sites of albumin and haemoglobin [2] . by a family of at least three structurally different dimeric enzymes called nitric oxide synthases (NOS), At high concentration in vivo, NO becomes a relatively non-specific effector molecule of the immune all of which are expressed in the kidney [1, 20, 21] . Generation of NO depends on the availability of -system with a key role in mediating host defense and, in the case of autoimmunity, self-destruction (Figure arginine, molecular oxygen and reduced nicotinamide adenine dinucleotide phosphate (NADPH ) as sub-1) [1, 20, 21] . Most of NO's cytostatic and cytotoxic potential is ascribed to the irreversible reaction with strates. Cofactors are a cytochrome P-450 type heme moiety, calmodulin, flavin dinucleotide ( FAD), flavin superoxide anion (O2-) to produce the potent oxidant peroxynitrite (ONOO-). During inflammation, high mononucleotide (FMA) and tetrahydrobiopterin (BH4). The generation of NO by all NOS isoforms output NO generation is often paralleled by increased production of superanions, thus promoting the formacan be inhibited by -arginine analogs such as -nitroarginine-methyl-ester (-Name) or -nitro-monomethyl-tion of peroxynitrite. Peroxynitrite itself is a highly cytotoxic radical mediating massive oxidative injury. arginine (-NMMA). Although some NOS isoform specific pharmacological blockade can be achieved with Peroxynitrite impairs the function of proteins by nitration of their tyrosine residues [32] . The formation of these compounds, truly isoform specific pharmacological NOS blockers are not yet available.
these nitrotyrosines can be detected by immunohistochemistry and has been used as an indicator for the The NO generated from -arginine is a highly reactive radical gas and is an important molecular messenger existence and activity of the tissue damaging NOS pathway. In addition through peroxynitrite, NO dir-[1, 20, 21] . NO plays a critical role in numerous biological processes ranging from neurotransmission to ectly inhibits key enzymes of the respiratory chain and of DNA synthesis by nitrolysation of their ironvasodilatation, and inflammation to cell phenotype regulation (Figure 1 ). At low physiologic concentra-containing catalytic elements and can also directly cause fragmentation in DNA. Inducible NO productions in vivo, NO acts locally as an important signalling molecule. NO has a greater diffusion coefficient than tion is also involved in the induction of apoptosis, a constitutively present cascade leading to programmed oxygen and rapidly diffuses through most cells without being utilized or reacting with intracellular molecules. cell death [2, 33] . Signalling of NO is mainly mediated by reactions with transition heme groups or critical thiol groups in NOS isoforms various molecules and with free radical intermediates. A prototype of the interaction of NO with heme groups The NOS isoforms were originally called neuronal, macrophage and endothelial NOS (nNOS, mNOS and is the binding and activation of the soluble form of guanylate cyclase, which increases cGMP-levels and eNOS ) according to the cell type from which the NOS enzymes were first cloned and in which they were mediates many of the biological effects of NO including vasodilatation, inhibition of platelet self aggregation believed to be principally expressed [21, 34] . We know now that there is considerable overlap in the distribuand platelet adhesion to endothelium. The action of NO is locally restricted, since once in the vascular tion of the NOS isoforms. A new nomenclature has been proposed where nNOS is NOS I, mNOS is NOS space, NO has only a half-life of a few seconds due to its rapid reaction with heme groups of haemoglobin. II and eNOS is NOS III, according to the order in which they were discovered [34] . Some prolongation of its biological intravascular halfBoth the neuronal and endothelial NOS are principally constitutively expressed [20, 21] . Both isoforms produce a rapid but short-lived production of NO in small amounts for signalling purposes. Their activity is increased by increasing intracellular Ca2+ concentrations involving binding of calmodulin. Although eNOS and nNOS are categorized as constitutive enzymes, recent studies have shown that the mRNA and protein production of both enzymes is somewhat regulated [20, 21] . For instance, nNOS is transcriptionally altered by variations in salt intake and after chronic hypoxia. eNOS gene transcription changes in response to laminar shear stress, transforming growth factor-b ( TGFb), oestrogen and hypoxia.
Endothelial NOS (eNOS, NOS III)
NOS continuously released by endothelial cells, represents the most potent endogenous vasodilator known. Mice with a disrupted eNOS gene are hypertensive and more susceptible to cerebral stroke [35] . In the kidney, endothelial NO synthesis is important in main-In the kidney, nNOS is found primarily in the macula densa and is involved in the control of glomerular tenance of regional vascular tone, renal blood flow and glomerular filtration rate ( Figure 1) [1,2] . There haemodynamics via tubulo-glomerular feedback and the release of renin [1, 2, 33] . is some evidence that NO via a pressure-independent mechanism limits mesangial cell proliferation and matrix production, including a down regulation of the Macrophage-type NOS (mNOS, NOS II) central profibrotic cytokine TGF-b (Figure 2 ) [36] [37] [38] .
In contrast to nNOS and eNOS, mNOS is not normally Within the kidney, endothelial NO production is present in most tissues and must be specifically induced thought to be a critical homeostatic factor which leading to the term inducible NOS (iNOS) [20, 21] . counterbalances the vasoconstrictive actions of angioThis isoform is not calmodulin-dependent and can be tensin II and diminishes angiotensin II driven hyperinduced by pro-inflammatory stimuli such as bacterial trophy and matrix production.
lipopolysaccharides, tumour necrosis factor-a, interleukin-1 and c-interferon. Induction of iNOS involves The L-arginine-eNOS paradox activation of the transcription factor NF-KB. Once In patients with essential or secondary hypertension activated, the iNOS enzyme produces NO in large and in certain animal models of renal disease, -quantities for prolonged time periods and its output arginine administration has been shown to reduce depends on the extracellular -arginine supply [23, 29] . blood pressure in parallel with increased NO and -Since iNOS has to be transcriptionally activated, there citrulline production [21, 29] . However, the mechanism is a delay of several hours between induction and by which -arginine supplementation increases endo-subsequent NO synthesis of this isoform. Mice with thelial NO synthesis is still unclear [29] . The half-disrupted iNOS genes are more susceptible to saturating -arginine concentration (K m ) for eNOS is intracellular pathogens and show a blunted hypotensin the rage of 1-10 mM. Plasma -arginine concentra-ive response to LPS [21, 35] . In the diseased kidney, tions in humans and rats are approximately 100 mM. iNOS expression is elevated in both infiltrating macroThe intracellular -arginine concentrations of endothel-phages and renal mesangial and tubular cells [39] . ial cells even when cultured in -arginine-free medium Low level constitutive expression of iNOS is found in is well above the K m of eNOS. Thus, eNOS should several renal tubule segments suggesting an uncharacalways be saturated and not dependent on extracellular terized homeostatic function of iNOS in these tissues -arginine supply. [21] .
Neuronal NOS (nNOS, NOS I)
The L-arginine-ornithine pathway NO produced by nNOS is an important neurotransmitter involved in memory, learning, sexual beha--Arginine is also a substrate for a group of enzymes viour, fluid homeostasis and peripheral vascular called arginases ( Figure 2 ) [2, 40] . While arginase I is resistance [20, 21] . nNOS null mice are normotensive mainly expressed in the liver as part of the urea cycle, and less susceptible to cerebral ischaemic injury [35] . arginase II is expressed in macrophages and in kidney tissues [40] . Arginases metabolize -arginine to the non-protein amino acid -ornithine and urea ( Figure  2 ) [28, 41] . Generation of -ornithine is the first step in the synthesis of polyamines and -proline.
The L-ornithine-polyamine pathway
The polyamines, putrescine, spermine and spermidine, are aliphatic molecules required for cell replication and differentiation and thus are necessary for the proliferative element of tissue repair. In mammals, polyamines are generated from -ornithine via the enzyme ornithine decarboxylase (ODC ), which is the major regulatory enzyme in polyamine synthesis ( Figure 2) [2,28,41]. ODC activity is low in quiescent cells and high in rapidly dividing cells. A rapid and substantial increase of ODC activity is one of the earliest events following the growth-stimulation of resting cells. ODC activity is highly regulated by a number of factors, but is also dependent on the availability its precursors -arginine and -ornithine. In a mouse model of carcinogenesis, it was shown that dietary -arginine restriction levels and was associated with significantly reduced ular filtration and tubular reabsorption [53] . In vitro, agmatine antagonized -arginine metabolism through tumour growth [42] .
iNOS and ODC,while stimulating endothelial NOS synthesis [54] [55] [56] . In order to know the importance of The L-ornithine-L-proline pathway this pathway in normal and diseased kidneys and the -Ornithine is also metabolized by ornithine-amino-role of -arginine intake on this pathway a number of transferase (OAT ) and P5C reductase to form -proline questions must be answered. These include: (i) does (Figure 2) [2,28,41]. -Proline accounts for approxi-the activity of ADC depend on endogenous or extramately 22% of the amino acid residues in mammalian cellular -arginine concentration, (ii) what factors collagens. It is, however, unclear whether collagen increase or decrease ADC activity, (iii) do ADC activsynthesis and build-up can be directly altered by dietary ity and agmatine concentrations change during renal manipulations in -arginine. Consistent with a role for injury and repair and (iv) does ADC compete with dietary -arginine in -proline synthesis are data show-NOS and arginase for substrate? Until these questions ing that liver OAT activity is regulated by dietary -are answered, it remains possible that some of the arginine intake [43] . In cultured cartilage a minimum observed effects of dietary -arginine restriction or of 20% of the -proline incorporated into collagen is supplementation are mediated through its metabolite generated from -ornithine [44] . In hormonally stimu-agmatine. lated rat mammary glands, -arginine is the major precursor for -proline used in synthesis of breast milk proteins and the enzyme cascade arginase, OAT and P5C reductase is activated [45] .
Endocrine functions of L-arginine

Competition between NOS and arginase pathway
-Arginine has also been shown to enhance the release of a number of hormones, including corticotrophin Because both NOS and arginase utilize -arginine as releasing hormone, prolactin, growth hormone, somasubstrate, competition between these pathways may tostatin, insulin, glucagon, cortisone and aldosterone, play a role in the course of renal diseases [2, 46, 47] . some of which have been implicated in tissue fibrosis Persistent expression of iNOS may favour continuous [1, 2] . Parenteral administration of large quantities of injury, while stimulation of arginase activity may sup--arginine stimulates release of pituitary growth horport tissue repair. Exemplary studies in dermal mone and has been used for decades as a test for wounding have shown that the initial injury is characgrowth hormone deficiency in humans. With regard to terized by a marked induction of iNOS and concomitthe -arginine-eNOS paradox discussed above, a ant high NO production [48, 49] . This is followed by recent study has shown that the blood pressure an increase in arginase activity which progressively lowering effect of -arginine administration is at least depletes the local environment of -arginine and shifts in part mediated through insulin release rather than -arginine metabolism toward polyamine and proline through increased substrate availability for endothelial synthesis, thus favouring tissue repair. In ATS-induced NO production [57] . glomerulonephritis, we have shown that -arginine metabolism is sequentially activated in a similar manner [50] . Early mesangial cell lysis was associated with iNOS induction while the later repair phase was Importance of dietary L-arginine intake associated with arginase activation and increased expression of the ODC and OAT genes.
A special feature of -arginine is that its intake is semiessential. Under normal physiological conditions endo-
The L-arginine-agmatine pathway genous -arginine synthesis is sufficient to maintain whole body -arginine metabolic homeostasis and dietary -arginine intake is dispensable [1,2,58,59]. Recently, using bovine brain tissues, a new -arginine metabolizing pathway producing agmatine was disco-Endogenous net -arginine synthesis occurs primarily in the proximal tubule of the kidney using the nonvered in mammalian tissues [1, 27] . The existence of this pathway in bacteria and plants has been known protein amino acid -citrulline as precursor [60] . Minor endogenous -arginine synthesis has been observed in for a long time. Agmatine is decarboxylated -arginine and the catalyzing enzyme is called -arginine decarb-endothelial cells and macrophages [1,2]. However, the rate of endogenous -arginine production is constant oxylase (ADC ). Agmatine has clonidine-displacing activity and like clonidine, can bind to and activate and in conditions of increased demand such as growth, tissue inflammation or wound healing, -arginine both alpha-2 adrenoceptors and imidazol-guanidine receptors [27] . ADC activity is high in normal rat intake may become critical [48, 59] . Studies in dermal wound healing and renal disease have shown that local kidney [51] . Using cortical kidney homogenates incubated with radiolabelled -arginine, agmatine generation -arginine levels markedly decrease [8, 23, 48] , consistent with the concept that exogenous dietary -arginine was less than ornithine/urea synthesis but much greater than NO/citrulline synthesis [52] . Local micro-infusion supply may become rate-limiting to the -arginine pathways. of agmatine into renal interstitium increased glomer-H. Peters et al. 1644 rate of matrix accumulation. The same appears to be Dietary L-arginine in renal injury and repair true in human disease. Rapidly progressing diseases, such as HIV-nephropathy, show marked overImpact of injury and repair on renal fibrosis expression of TGF-b, while slowly progressing diabetic A hallmark of both experimental and human chronic nephropathy shows more slowly increasing TGF-b renal disease is the progressive expansion of extracellu-over-expression [64] . lar matrix, which impairs renal function and leads to
In addition to the severity and the nature of tissue organ failure [61] . It is our current hypothesis that the injury, the degree of TGF-b over-expression and the extent of renal fibrosis results from two major vari-subsequent matrix deposition are influenced by factors ables: the extent of tissue injury and the activity of the directly interacting with the repair process [33, 62, 65] . tissue repair process which follows [33, 62] . Well-known Over the last years, the octapeptide angiotensin II has injurious stimuli to the kidney are increased blood been identified as key factor determining the activity pressure, hyperglycaemia or autoimmune tissue of TGF-b and the repair process [65] . In addition to destruction. The degree of the resulting tissue injury its impact on hypertensive tissue injury, there is subdepends on the frequency, duration and severity of stantial evidence that angiotensin II directly induces these injurious stimuli.
and promotes TGF-b over-expression, which in turn Injury to the kidney leads to a predictable repair promotes further matrix expansion [66, 67] . Very recent reaction, characterized by matrix expansion [61] . Over-data have shown that angiotensin II prevents the expression of the profibrotic cytokine TGF-b has been normal action of TGF-b to down-regulate its own identified as a key factor mediating, orchestrating and receptors [68] which suggests that angiotensin II may determining the activity of the molecular cascades prevent TGF-b from self-terminating the repair leading to expansion of extracellular matrix in various response and could be a key event in shifting acute organs (Figure 3 ). TGF-b strongly induces the syn-wound repair to progressive tissue fibrosis. In addition, thesis of most matrix proteins, inhibits matrix degrada-the direct action of angiotensin II on TGF-b overtion and stimulates local expression of matrix binding expression may well explain the experimental and receptors. Blocking the actions of TGF-b with neutral-human experience that pharmacological angiotensin II izing antibodies has been shown to prevent excessive blockade prevents renal fibrosis more effectively than matrix accumulation after injury in a number of tissues other anti-hypertensive drugs. Another important including the kidney [61, 63] . A number of factors determinant of ongoing matrix accumulation seems to known to be injurious to the kidney at the cellular be insufficient endogenous production of the proteolevel have now been shown to directly induce TGF-b glycan decorin, a naturally occurring TGF-b antagonover-production, including angiotensin II, mesangial ist [69] . Experimental strategies supplying decorin have cell stretch, fluid shear stress, high glucose levels, been shown to lead to a direct and injury-independent hypoxia, immune-complexes, protein trafficking, plate-decrease in TGF-b over-expression [70, 71] . let derived growth factor and TGF-b itself (Figure 3 ) [62] . The degree of TGF-b over-expression generally Thy 1 glomerulonephritis correlates with the rate of matrix accumulation. Mesangial cell lysis in ATS-induced glomerulonephritis While most experimental renal diseases involve conis a strong and rapid inducer of glomerular TGF-b tinual and overlapping cycles of tissue injury and overproduction and subsequent matrix production. repair, the model of ATS-induced glomerulonephritis Other stimuli such as increased blood sugar moderately involves a sequence of distinct phases of 'injury' and increase renal TGF-b production resulting in a slow 'repair', making it amenable to dissection of effects on both processes. Injection of an antibody to a Thy 1-like epitope causes dose-dependent complementmediated lysis of a portion of glomerular mesangial cells [33] . This 'injury' is followed by a marked upregulation of TGF-b and a fibrotic 'repair' phase with glomerular matrix expansion. Although the injury, namely antibody-mediated mesangial cell lysis, is not shared by all renal diseases, the histological and molecular pattern of the acute repair reaction is very similar to that found in both chronic experimental and human renal disease [62] . Acute and chronic, experimental and human kidney disease, all share the feature that, where there is tissue fibrosis there is overexpression of TGF-b. Thus, we believe that studies on matrix expansion in ATS-nephritis are relevant for 
of inducible NO production in renal tissue injury has nephritis [33, 72] .
been shown in models of acute ischaemic renal failure Using the ATS-induced model of glomerulonephritis, and lupus nephritis [74, 77] and has been suggested in we have recently completed a series of four studies, experimental kidney transplant rejection [73] . comparing and contrasting the effects of both -In our first study, we found that restriction of -arginine restriction and -arginine supplementation arginine intake in the form of low protein feeding in the same model and under very similar consignificantly prevented ATS-induced mesangial cell ditions [18, 19, 22, 23] . With major emphasis on theralysis as well ( Figure 4B ) [18] . Addition of -arginine peutic potential, we related both restriction and to the drinking water to normalize -arginine intake supplementation of dietary -arginine intake to the increased mesangial cell lysis to the same extent seen two major determinants of renal fibrosis: (i) in animals on a normal protein diet. Although para-'injury'(here ATS-induced mesangial cell lysis) and (ii) meters of NO synthesis were not measured, these 'repair' ( TGF-b over-expression and matrix accumulafindings suggest that dietary -arginine restriction tion). In the case of -arginine restriction, -arginine limits glomerular tissue injury by limiting the substrate intake was reduced to the level found in low protein for cytotoxic NO generation, a mechanism which may diet (6% casein). In the case of -arginine have great importance in the beneficial effects of low supplementation, 1% -arginine was given in the protein diets in renal disease [2, 18] . drinking water. This supplementation protocol has been used frequently in previous studies and increases Dietary L-arginine supplementation in immunologic -arginine intake in rats on a normal protein diet renal injury approximately 4-fold. To investigate the effects of -arginine on renal injury, rats were pretreated with -In our second study, 1% -arginine in the drinking arginine restriction or supplementation for 7 days water was given rats on a normal protein diet [23] . before ATS injection. The severity of ATS-induced We were uncertain whether -arginine supplementation mesangial cell lysis was examined 4-6 h after disease would worsen ATS-induced glomerular injury. Studies induction, where previous studies had shown that by Klahr's group have shown that -arginine mesangial cell lysis was almost complete. To investigate supplementation may have important antithe effects of -arginine on renal repair, -arginine inflammatory actions [7] . In models of obstructive restriction or supplementation were started after dis-nephropathy and puromycin-induced nephrosis, -argiease induction and continued for 6-7 days, a time nine feeding markedly reduced macrophage infiltration point when TGF-b over-expression and rate of matrix and increased endogenous corticoid production, both expansion is maximally induced.
of which may be protective in inflammatory tissue injury. However, confirming and expanding our initial study
Dietary L-arginine in renal injury
we found that supplementing -arginine intake before ATS-injection significantly increased mesangial cell In renal tissue injury, the role of dietary -arginine lysis measured at 6 h compared to nephritic rats with intake is primarily defined through its metabolite NO normal -arginine intake ( Figure 4C ) [23] . In addiand both detrimental and protective actions of modify-tional groups of rats, -arginine administration was ing -arginine intake have been shown (Figure 1 ) stopped 16 h after antibody injection to let the repair [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 23] . While enhanced endothelial NO production process proceed with normal -arginine intake. The appears to mediate protective effects, -arginine metab-fibrotic response, as measured by glomerular TGF-b olized through the high output iNOS isoform seems to over-expression and histological matrix accumulation, be a critical effector molecule in immune mediated was significantly increased 6 days after disease inductissue damage.
tion as compared to disease control animals that had never been exposed to high -arginine. This finding is Dietary L-arginine restriction in immunologic renal consistent with the concept that the extent of repair injury reflects the degree of the initial injury. Interestingly, -A central feature of immune-mediated tissue injury is arginine administration did not appear to reduce the a marked local de novo expression of iNOS and a high inflammatory response following ATS-injection since NO production, which has been demonstrated in macrophage infiltration and glomerular iNOS and models of immune-complex-glomerulonephritis, ATS-protein levels did not differ in -arginine supplemented induced glomerulonephritis, lupus nephritis and trans-and non-supplemented rats. However, 6 h after disease plant rejection [18, 23, 46, [73] [74] [75] [76] . In ATS-induced induction, plasma levels of -arginine and nitrate/ glomerulonephritis, our laboratory has shown that the nitrite, the stable end products of NO, were significinitial mesangial cell lysis is mediated through cytotoxic antly higher in -arginine supplemented rats than in amounts of NO produced by iNOS ( Figure 4A ) [18] . those drinking tap water only. In addition, NO producIn rats with short-term pretreatment of the NOS tion by cultured glomeruli harvested 6 h after ATSinjection was highly dependent on the extracellular inhibitor -NMMA before ATS administration, mes- -arginine concentration with a marked increases in ameliorate anti-glomerular basement membrane glomerulonephritis [87] . NO production between the -arginine concentrations seen in nephritic rats without and with -arginine supplementation. These results strongly suggest that -Dietary L-arginine in hypertensive renal injury arginine supplementation can worsen tissue injury and Beneficial effects of dietary -arginine supplementation subsequent fibrosis in immune-mediated renal disease have been reported in models of renal disease characthrough a substrate-dependent mechanism. Similar detterized by increased renal blood pressure where there rimental effects of -arginine administration have been is likely to be a component of hypertensive tissue demonstrated in experimental acute tubular necrosis, injury. -Arginine supplementation has been reported immune-mediated dermal vasculitis, hypoxic lung to improve impaired renal haemodynamics in 5/6 nephinjury, toxic colitis and brain reperfusion [78] [79] [80] [81] [82] . These rectomy, ureteral obstruction, puromycin-induced models appear to share the feature that NO synthesis nephrosis and nephropathy secondary to diabetes, saltis greatly increased through induction of iNOS.
sensitive hypertension, cyclosporin, radiocontrast In conclusion, our studies on manipulations of drugs or ageing [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . This reduction in hypertensive dietary -arginine intake are consistent and reveal injury is reflected in a reduction in the fibrotic repair that -arginine restriction limits and -arginine response in 5/6 nephrectomy, ureteral obstruction and supplementation augments mesangial cell injury nephropathy secondary to salt-sensitive hypertension, (Figure 4B and C ) . The data show that this occurs cyclosporin or ageing [5, 9, 11, 15, 16 ] . Similar to the through a substrate-dependent effect on NO producvascular dysfunction seen in essential and secondary tion by iNOS.
hypertension, these models seem to share the feature of chronically deficient renal NO synthesis [2].
Immune-complex glomerulonephritis
Glomerular hypertension contributes to tissue injury in many chronic renal disorders. Such injury is not While studies of ATS-induced glomerulonephritis, lupus nephritis, transplant rejection and acute tubular generally characterized by increased expression of inducible NOS. Dietary -arginine supplementation is necrosis point to a critical role for iNOS in renal tissue damage, experimental immune-complex glomerulo-believed to overcome chronic NO deficiency by enhancing endothelial NO production, increasing vasodilnephritis appears to be an exception. While there is substantial evidence that iNOS is expressed and active ation and thereby limiting hypertensive injury to the kidney ( Figure 1 ). This view is supported by data in this model of kidney disease [46, 75, 76, 83, 84] , the high NO production does not seem to contribute to indicating increased NO synthesis following -arginine administration in models of subtotal nephrectomy, tissue damage. Experiments designed to decrease NO production via iNOS, including the use of systemic ureteral obstruction and Dahl/Rapp nephrosclerosis.
In ureteral obstruction and in salt-sensitive Dahl/Rapp arginase administration to deplete -arginine levels and the use of non-specific NOS inhibition showed rats, -arginine administration also reduced arterial pressure [7, 88] . In rats with 5/6 nephrectomy, -arginincreased signs of renal damage [85, 86 ] . Consistent with these findings are recent data demonstrating that ine supplementation normalized glomerular pressure [6 ] . Thus, the main therapeutic effect of -arginine genetic disruption of the iNOS gene in mice does not supplementation in these models appears to be a tial NO has shown in vitro (Figure 2 
endothelial NO production. However, indices for NO synthesis (glomerular NO production, plasma and urinary NO levels) did not differ between diseased
Dietary L-arginine in renal tissue repair animals on the same diet with and without -arginine, although -arginine supplementation significantly As mentioned above, the ATS model is characterized increased arterial -arginine levels. It may be that in a by a distinct 'repair' phase. Although glomerular normotensive model such as ATS nephritis, the impact haemodynamic changes have been reported following of -arginine supplementation on endothelial NO syn-ATS-injection, the degree of the fibrotic response is thesis is below the detection limit of our methods, but mainly attributed to the degree of immunologic injury. it may also be that other pathways are involved. In our third and fourth study, both -arginine restricTaken together, in rats following induction of mesantion or supplementation were started after diseases gioproliferative glomerulonephritis both dietary -argiinduction [19, 22] , when mesangial cell lysis had nine restriction and -arginine supplementation occurred and the same degree of tissue injury had been significantly limit glomerular TGF-b over-expression achieved. After 6-7 days, a time where previous studies and subsequent matrix accumulation. Because normal had demonstrated that TGF-b over-expression and the -arginine intake produces more severe disease than rate of matrix expansion is maximal, therapeutic effects either restriction or supplementation, these data sugwere determined. gest a bell-shaped effect of -arginine intake on the renal repair process.
Dietary L-arginine restriction in renal tissue repair
In the third study, we found that restriction of -arginine intake in rats on isocaloric normal protein From rats to man diet limited glomerular TGF-b and matrix accumulation comparable to that seen in rats fed a low protein -Arginine research in rat models has improved our diet [19] . In contrast, when low protein was combined knowledge and understanding of renal physiology, with -arginine in the drinking water to normalize -pathophysiology and pathology. Although animal arginine intake, the beneficial effect of protein restric-models give us critical information on the potential of tion was abolished. Though it has yet to be proven, new therapeutic approaches, it remains hazardous to we speculated that this effect of -arginine restriction extrapolate experimental results to human renal dison repair may be due to local limitation of substrate ease. With this precaution in mind, we will speculate for polyamine and -proline production which may on the therapeutic potential of modifying dietary -become rate-limiting for the proliferative and fibrotic arginine intake for human renal disease. repair responses (Figure 2) . Together with the beneficial action of -arginine restriction on immune tissue L-Arginine metabolism in humans injury, these data strongly suggest that -arginine is a key amino acid in the therapeutic actions of low All of the -arginine metabolizing pathways expressed protein diets.
in rodents, are expressed in humans, including eNOS, bNOS, iNOS, argininase, ODC, OAT and ADC. Thus, Dietary L-arginine supplementation in renal tissue repair -arginine effects seen in rodent models of renal disease should be very similar in humans. However, there is In the fourth study, we determined the effect of some debate whether the iNOS enzyme is actually supplementing 1% -arginine in the drinking water on functioning in humans. The discussion results from the repair of ATS glomerulonephritis [22] . Because we early data showing that rodent cells in vitro produce had shown anti-fibrotic effects of dietary -arginine large amounts of NO in response to simple immunolrestriction [19] and others had reported anti-fibrotic ogic stimuli, while human macrophages in vitro show effects of dietary -arginine supplementation in other little or no response [89] . However recently, evidence models of renal disease [5, 9, 11, 15, 16 ] , we were uncerhas accumulated demonstrating that human iNOS is tain whether increasing dietary -arginine intake after active in vivo, but requires more specific immunologic ATS-injection would worsen or ameliorate the glomerstimuli which are difficult to mimic in vitro. An active ular fibrotic response.
iNOS enzyme has been demonstrated in several We found that -arginine supplementation started inflammatory human diseases including tuberculosis, after mesangial cell lysis had occurred, significantly urinary tract infection, inflammatory arthritis, leishreduced glomerular TGF-b over-expression and matrix maniosis and immunodeficiency virus (HIV ) type 1 in animals fed a normal protein diet [22] . The antiencephalitis and renal transplant rejection [89] [90] [91] [92] [93] [94] [95] . fibrotic effect was similar to that seen in nephritic rats Also, evidence for an active tissue damaging NO fed a low protein diet. Combined therapy of low pathway in humans has been provided by immunoprotein diet and 1% -arginine produced additional histochemical detection of nitrotyrosine [32] , with reductions in pathological glomerular TGF-b overdemonstration of increased staining in a number of expression and matrix expansion. Given the antiproliferative, anti-fibrotic and TGF-b-reducing poten-human diseases, including atherosclerosis, myocardial ischaemia, inflammatory bowel disease, septic lung in an additional anti-fibrotic effect in the presence of angiotensin II blockade? (iii) Is -arginine disease, renal manifestations of Wegener's granulomatosis and kidney transplant rejection [32, 95, 96 ] . supplementation really feasible? To supplement dietary -arginine in humans would require -arginine in the Furthermore, induction of the iNOS enzyme has been demonstrated in a number of immunologic human range of 15-30 g/day which equals an additional daily protein intake of 15-30 g. Will this be practical in renal diseases ( Table 1) [95] [96] [97] [98] [99] . Interestingly, in the studies by Kashem et al. and Furusu et al. the degree patients with chronic renal insufficiency who are supposed to restrict their daily protein intake to approxiof iNOS expression correlated with the severity of histological signs of renal damage supporting the con-mately 60 g? (iv) Is the beneficial effect of -arginine supplementation indeed mediated through NO and can cept that a destructive iNOS pathway is operating in human disorders [97, 98] .
we mimic its therapeutic potential with NO donating drugs in doses designed to overcome deficient endothelial NO production, but far below NO levels involved Are we ready for human trials?
in tissue injury? This strategy would overcome the Although angiotensin II blockade and dietary protein detrimental effects of -arginine supplementation in restriction slow the rate of deterioration, halting the situations where iNOS is activated and would be easier progressive course of chronic human renal disease to add to a low protein diet. If so, would we be advised remains one of the greatest challenges in nephrology. to start a human trial testing these drugs rather than Thus, it may not be surprising that the positive effects -arginine supplementation? of -arginine administration in experimental renal diseases has resulted in some enthusiasm for human trials.
Summary
However, as outlined in this review, dietary -arginine supplementation has the potential both to protect and Experimental studies have shown both therapeutic and to harm the kidney. Animal data has provided substandetrimental consequences of modifying dietary -argintial evidence that in renal diseases where iNOS is ine intake in renal diseases which likely reflect the increased, -arginine supplementation can worsen renal complexity of -arginine metabolism. -Arginine intake injury and the subsequent fibrotic response through is semi-essential and provides substrate for a number enhancing generation of cytotoxic NO suggesting a of -arginine metabolites involved in renal pathology. dark side of -arginine supplementation. This is parDietary -arginine restriction has been identified as a ticularly relevant to immune-mediated inflammatory key mediator of the beneficial effects of low protein disorders, where the use of -arginine supplementation diets on human renal fibrosis. Supplementing dietary as a therapy may be potentially harmful and -arginine -arginine in renal diseases with increased iNOS expresrestriction may be warranted. sion appears to be detrimental and thus, may be On the other hand, -arginine supplementation may harmful in immune-mediated human kidney disorders. be useful in some human renal diseases, especially in Increasing -arginine intake is beneficial in experilater stages when inflammation is over and the promental models of hypertensive renal disease. Based gressive loss of renal function is mainly driven by upon available data, we believe additional questions glomerular hypertension. However, we believe that must be answered experimentally, not only to prevent there are some critical questions which should be an adverse outcome in humans, but to enhance our addressed before human trials begin. (i) In what renal chances of human trials which will result in substandisorders will -arginine supplementation be safe? tially better amelioration of disease than currently How is iNOS expressed in hypertensive and diabetic available. nephropathy? (ii) How effective can -arginine supplementation be? The data in hypertensive models 
